SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) September 14, 2000
BICO, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) indentification No.)
2275 Swallow Hill Road, Bldg. 2500, Pittsburgh, Pennsylvania 15220
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 429-0673
_________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
BICO, Inc. subsidiary, Diasensor.com, Inc.,
announced today that two key personnel have joined
the management team of MicroIslet, Inc. following
recently revealed preclinical success in treating
insulin dependent diabetes. Fred R. Kohen Ph.D.
assumes the position of Vice President,
Preclinical and Clinical Development; Mayank Patel
will become the Director of Engineering and
Manufacturing for MicroIslet, Inc.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
BICO, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: September 14, 2000
BICO, INC.'S SUBSIDIARY, DIASENSOR.COM, ANNOUNCES FIRST
MEMBERS OF MICROISLET, INC. MANAGEMENT TEAM
Pittsburgh, PA - September 14, 2000 - BICO, Inc.
(OTCBB:BICO) subsidiary, Diasensor.com, Inc., announced
today that two key personnel have joined the management team
of MicroIslet, Inc. following recently revealed preclinical
success in treating insulin dependent diabetes. Fred R.
Kohn Ph.D. assumes the position of Vice President,
Preclinical and Clinical Development; Mayank Patel will
become the Director of Engineering and Manufacturing for
MicroIslet, Inc.
Diasensor.com recently increased its holdings to twenty
percent in MicroIslet, which is located in La Jolla, CA.
Both Dr. Kohn and Mr. Patel have substantial experience
in the pharmaceutical and biotech industries. Prior to
joining MicroIslet, Inc. Dr. Kohn was Director of Project
Management at Skye Pharma, Inc (formerly DepoTech
Corporation). At Skye Pharma, Dr. Kohn headed the project
team responsible for the development of sustained-release
encapsulated morphine for the treatment of acute post
surgical pain. Previously, he was Director of product
development at Desmos, Inc., where he was responsible for
all aspects of development of a therapeutic protein for
periodontal disease. Before joining Desmos, Dr. Kohn was
Senior Scientist and acting head of Immunology at Xoma
Corporation, where he conducted preclinical research in
their infectious and autoimmune disease programs. Dr. Kohn
received his Ph.D. in Pharmacology from the University of
Minnesota. Mr. Patel is a chemical engineer with eight years
of experience in pharmaceutical and diagnostic product
manufacturing. Mr. Patel has broad experience with an
extensive background in aseptic pharmaceutical equipment
design, commissioning, validation, and automation. He was
formerly Senior Process Engineer at Sequenom, Inc., where he
was responsible for implementing the production of
diagnostic test kits for chip based DNA analysis. Mr. Patel
has a chemical engineering degree and an MBA in Operations
Management from Rutgers University.
John F. Steel IV, CEO of MicroIslet, Inc., indicated
that additional key personnel would be joining the company
in the near term to build on the ongoing successes and
opportunities for MicroIslet, Inc.
BICO, Incorporated has its corporate offices in
Pittsburgh, PA and is involved in the development and
manufacture of biomedical devices and environmental
products. Subsidiary Diasensor.com, Inc. owns the patents,
technology, marketing, and distribution rights to the
Diasensor 2000 noninvasive glucose monitor, which was
developed by BICO and is currently in the FDA approval
process. BICO owns 52% of Diasensor.com, which is also
located in Pittsburgh, PA.
FOR FURTHER INFORMATION, CONTACT:
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
INVESTOR RELATIONS NEWSLINE NUMBER: 1.800.357.6204
WEBSITE: www.bico.com
